My watch list
my.chemeurope.com  
Login  

Ixabepilone



Ixabepilone
Systematic (IUPAC) name
(1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7,
9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol-
4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]
heptadecane-8,12-dione
Identifiers
CAS number 219989-84-1
ATC code L01DC04
PubChem 6445540
Chemical data
Formula C27H42N2O5S 
Mol. mass 506.698 g/mol
SMILES search in eMolecules, PubChem
Synonyms Azaepothilone B
Pharmacokinetic data
Bioavailability N/A
Protein binding 67 to 77%
Metabolism Extensive, hepatic, CYP3A4-mediated
Half life 52 hours
Excretion Fecal (mostly) and renal
Therapeutic considerations
Pregnancy cat.

D(US)

Legal status

-only(US)

Routes Intravenous infusion

Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.

Additional recommended knowledge

On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. ([1]). Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra.


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ixabepilone". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE